JACOBS LEVY EQUITY MANAGEMENT, INC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 134 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 5.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,153,728
+160.3%
2,353,528
+247.7%
0.02%
+171.4%
Q2 2023$1,211,570
-71.0%
676,855
-37.0%
0.01%
-73.1%
Q1 2023$4,182,038
-45.3%
1,075,074
-52.2%
0.03%
-50.0%
Q4 2022$7,647,957
-11.5%
2,249,399
+42.1%
0.05%
-23.5%
Q3 2022$8,641,000
+25.5%
1,582,524
+3.6%
0.07%
+28.3%
Q2 2022$6,887,000
+40.8%
1,527,040
+130.1%
0.05%
+60.6%
Q1 2022$4,890,000
+482.8%
663,512
+716.6%
0.03%
+450.0%
Q2 2021$839,000
+27.5%
81,257
+91.1%
0.01%0.0%
Q4 2020$658,000
-74.1%
42,519
-67.9%
0.01%
-76.0%
Q4 2019$2,540,000
+262.9%
132,505
+82.0%
0.02%
+177.8%
Q3 2019$700,000
+154.5%
72,800
+148.5%
0.01%
+80.0%
Q4 2018$275,000
-44.7%
29,300
+0.3%
0.01%
-28.6%
Q3 2018$497,000
-51.9%
29,200
-52.0%
0.01%
-56.2%
Q2 2018$1,033,000
+48.0%
60,800
+16.9%
0.02%
+33.3%
Q1 2018$698,000
+36.6%
52,000
-2.3%
0.01%
+33.3%
Q4 2017$511,000
+89.3%
53,200
+116.3%
0.01%
+80.0%
Q3 2017$270,000
+126.9%
24,600
+86.4%
0.01%
+66.7%
Q2 2017$119,000
-59.2%
13,200
-42.0%
0.00%
-50.0%
Q1 2017$292,000
-28.8%
22,740
-47.8%
0.01%
-25.0%
Q4 2016$410,000
+5.7%
43,600
+9.3%
0.01%
+14.3%
Q3 2016$388,000
+59.0%
39,900
+9.9%
0.01%
+40.0%
Q2 2016$244,00036,3000.01%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Consonance Capital Management LP 4,767,078$80,993,0005.22%
Palo Alto Investors LP 4,663,324$79,230,0003.17%
DOHENY ASSET MANAGEMENT /CA 282,945$4,807,0002.61%
Private Capital Advisors, Inc. 416,900$7,083,0002.22%
Sandia Holdings, LLC 119,739$2,034,0000.91%
Virtus ETF Advisers LLC 44,986$764,0000.68%
Birchview Capital, LP 50,000$850,0000.58%
Schonfeld Strategic Advisors LLC 415,600$7,061,0000.38%
EMERALD ADVISERS, LLC 561,317$9,537,0000.36%
Kazazian Asset Management, LLC 20,672$351,0000.32%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders